Telephone follow-up by a community pharmacist on day 5 of encorafenib, binimetinib, and cetuximab therapy detected visual symptoms that led to diagnosis of grade 2 serous retinal detachment, enabling dose adjustment and continued treatment until day 260. (Yakugaku Zasshi)
Community pharmacy monitoring detects early ocular toxicity in BRAF V600E-mutated CRC
The CRC Digest